Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions.

BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the offering.

Mineralys intends to use the net proceeds from the offering to fund a portion of the $200.0 million upfront payment for the repurchase of the royalty obligation under its license agreement with Tanabe Pharma Corporation. Earlier today, Mineralys announced entering into a $500 million committed debt facility with funds managed by Pharmakon Advisors, LP.